Merck names Oosthuizen head of new cancer unit

With the loss of exclusivity looming in the next few years for blockbuster Keytruda pembrolizumab, Merck & Co. Inc. (NYSE:MRK) is reorganizing its human health business into two separate units, with new leadership at the helm of each. 

The new oncology business unit will be led by Jannie Oosthuizen, who was named EVP and president of oncology and MSD International. Oosthuizen was previously SVP and president of Merck Human Health U.S. The other newly formed business group, the specialty, pharma and infectious diseases business unit, will be led by Brian Foard, who was appointed as EVP and president of the unit, effective March 2. He most recently was EVP and head of the specialty care business unit at Sanofi (Euronext:SAN; NASDAQ:SNY)...